Current cancer biomarkers present variability in their predictive power and demonstrate
limited clinical efficacy, possibly due to the lack of functional relevance of biomarker genes …

Tumor recurrence is the major cause of death in lung cancer treatment. To date, there is no
clinically applied gene expression-based model to predict the risk for tumor recurrence in …

Abstract In Non—Small-cell lung cancer (NSCLC), molecular profiling of tumors has led to
the identification of gene expression patterns that are associated with specific phenotypes …

Few prognostic biomarkers are approved for clinical use primarily because their initial
performance cannot be repeated in independent datasets. We posited that robust …

Gene expression profiling has identified cancer prognostic and predictive signatures with
superior performance to conventional histopathological or clinical parameters …

With the emergence of genomic profiling technologies and selective molecular targeted
therapies, biomarkers play an increasingly important role in the clinical management of …

Lung cancer is the principal cause of leading cancer-related incidence and mortality in the
world. Various studies have excavated the potential prognostic biomarkers for cancer …

Background A more accurate prognosis for non-small-cell lung cancer (NSCLC) patients
could aid in the identification of patients at high risk for recurrence. Many NSCLC mRNA …

Background Lung cancer is the leading cause of cancer-related mortality. Improved
understanding in the molecular biology and genetics of lung cancer has resulted in the …

Background The advent of personalized medicine requires robust, reproducible biomarkers
that indicate which treatment will maximize therapeutic benefit while minimizing side effects …